In House Committee·Last action 454 days ago

HR679 Aims to Reverse FDA Changes on Abortion Pill

Officially: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

HR679 seeks to undo recent FDA changes to the abortion pill mifepristone. Affects women and healthcare providers by altering access and regulations.

Where it stands

Sitting in House Committee

No vote scheduled. Constituent contact is what moves bills out of committee.

What this bill actually does

Reversal of FDA changes: Seeks to undo the FDA's January 2023 modifications to mifepristone regulations.
Restoration of previous rules: Aims to bring back the earlier risk evaluation and mitigation strategies for the pill.

↓ Why your message matters here

This bill is sitting in committee with no scheduled vote — which means a small number of constituent messages can decide whether it moves forward or quietly dies.

The debate

What people are saying about this bill

✓Arguments in support

Enhances patient safety: Supporters argue that in-person dispensing ensures that patients receive necessary exams and follow-up care, reducing risks like severe bleeding.
Reduces adverse events: By reinstating the requirement to report serious complications, the bill aims to better monitor and address risks associated with mifepristone.
Prevents unregulated distribution: The bill seeks to curb the risk of counterfeit drugs and unmonitored self-administration by restricting mail-order access.

✕Arguments against

Limits access to safe medication: Opponents argue that mifepristone is a safe and effective method for early abortions, and the bill would unnecessarily restrict access.
Increases healthcare costs: The requirement for in-person visits could raise costs for patients, particularly those who have to travel long distances.
Ignores FDA's evidence-based updates: Critics say the FDA's changes were based on decades of data showing low risks, and the bill undermines this scientific process.

Where this bill is in the process

Legislative timeline

✓

Introduced

Introduced in House

—

●

House Committee

Under House committee consideration

Latest: Referred to the House Committee on Energy and Commerce. (1/23/2025)

JAN 23

○

House Floor Vote

Voted on by House

—

○

Passed House

Approved by House

—

○

Senate Review

Sent to Senate for consideration

—

○

Passed Both Chambers

Approved by both House and Senate

—

○

Signed into Law

Signed by the President

—

For more detail

Menu

HR679 Aims to Reverse FDA Changes on Abortion Pill

What people are saying about this bill

Legislative timeline

Read deeper